期刊文献+

初诊原发性甲状腺淋巴瘤临床病理因素分析 被引量:1

下载PDF
导出
摘要 原发性甲状腺淋巴瘤(PTL)极为罕见,发病率仅占甲状腺恶性肿瘤的1%-5%,占结外淋巴瘤的3%[1],年发病率约为2/100万[2]。由于PTL发病率极低,临床特征不明显,易误诊为甲状腺炎或甲状腺癌。该疾病临床表现及组织学表现均具有异质性,大多数PTL是B细胞来源的非霍奇金淋巴瘤,其中弥漫大B细胞淋巴瘤(DLBCL)为最常见的组织学类型,其次是边缘区和滤泡性淋巴瘤[1]。
出处 《中国实验诊断学》 2022年第2期180-184,共5页 Chinese Journal of Laboratory Diagnosis
基金 吉林省财政厅吉林省卫生科研人才专项(2018SCZ031,2019SCZ055) 吉林省卫生计生委吉林省卫生技术创新项目(3D517ED43430) 吉林省科技发展计划项目(20180101124JC)
  • 相关文献

参考文献5

二级参考文献47

  • 1李德鹏,李坤成,马云川,苏玉盛,张琳瑛,尚建文.胶质瘤的^(18)F-FDG PET影像分析[J].中国医学影像技术,2006,22(6):941-944. 被引量:9
  • 2Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139. 被引量:1
  • 3Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41. 被引量:1
  • 4Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006. 被引量:1
  • 5Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205. 被引量:1
  • 6Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045. 被引量:1
  • 7Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 2010, 9 I: 258-266. 被引量:1
  • 8Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23:5027-5033. 被引量:1
  • 9Habermama TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in old- er patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24:3121-3127. 被引量:1
  • 10Tilly H, Dreyling M. ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin' s lymphoma: ESMO clinical recom- mendations for diagnosis, treatment and follow-up. Ann Oncol, 2008, Suppl 2:ii67-69. 被引量:1

共引文献263

同被引文献20

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部